Peptide Therapy · Selank, Semax & Epitalon

Selank, Semax, and Epitalon: Three Peptides, Three Different Evidence Stories

An evidence-first comparison of Selank, Semax, and Epitalon: anxiety, neuroprotection, and circadian-longevity hypotheses, the human evidence, and current FDA compounding status.

Medical reviewer: Dr. Kish Carlton, MD · Mind Body Spirit Medicine · Last reviewed · 8 min read

Episode thumbnail featuring Dr. Kish Carlton with the headline “Three Peptides. Calm. Focus. Reset?” and labels for Selank, Semax, and Epitalon.

Watch the episode

Selank, Semax, and Epitalon are frequently placed in the same online category: peptides for a calmer brain, sharper thinking, better sleep, or a longer life. That framing is convenient, but scientifically misleading. They are different molecules, built around different hypotheses, and supported by very different kinds of evidence.

Why are they grouped together?

All three are short synthetic peptides associated with Russian peptide research. All three are now marketed online beyond their original research contexts, often as nasal sprays or injections. And for all three, confident claims have moved faster than high-quality, independently replicated human trials.

That shared history does not make them a single therapeutic class. It does explain why they form such a compelling comparison: three different molecular ideas aimed at three deeply connected dimensions of human function—stress, neural adaptation, and biological timing.

Selank: the anxiety hypothesis

Selank is a seven-amino-acid peptide derived from the immune-related peptide tuftsin. Proposed pathways include gamma-aminobutyric-acid signaling, neurotrophic signaling, and stress-related gene expression.

Small clinical studies, largely from one research ecosystem and often published in Russian, report preliminary anxiolytic effects. A comparative study involving 60 patients reported favorable effects relative to phenazepam. This is a signal worth studying, but it is not a large, diverse, independently replicated evidence base. Selank is not established as a standard anxiety treatment or reliable cognitive enhancer, and long-term human safety remains poorly characterized.

Semax: the neuroprotection hypothesis

Semax is a seven-amino-acid analog derived from a fragment of adrenocorticotropic hormone. Proposed mechanisms involve brain-derived neurotrophic factor, neuronal plasticity, inflammatory signaling, and responses to cerebral ischemia.

A placebo-controlled functional-magnetic-resonance-imaging study in 24 healthy volunteers found short-term differences in default-mode-network measurements after intranasal Semax. Other studies have explored ischemic-stroke rehabilitation and optic-nerve disease. These results suggest biological activity, but biological activity is not the same as a proven improvement in cognition, dementia risk, attention, migraine, or long-term neurological outcomes.

The evidence is limited by small samples, geographic concentration, surrogate outcomes, and insufficient independent replication.

Epitalon: the circadian-resetting and longevity hypothesis

Epitalon is a four-amino-acid peptide—Ala-Glu-Asp-Gly—also spelled Epithalon or Epithalone. It must not be confused with Epithalamin, a complex bovine pineal extract used in some older studies.

Epitalon is promoted for circadian regulation, telomerase activation, telomere lengthening, and longevity. The circadian question is especially intriguing. Pineal signaling, melatonin timing, the central clock, and peripheral organ clocks all participate in the body’s temporal organization. The possibility that a peptide might influence circadian phase or help restore alignment after disrupted timing is biologically fascinating—and distinct from simply acting as a sedative.

Its most discussed evidence remains mechanistic. A 2003 experiment reported telomerase activation and telomere elongation in cultured human fetal fibroblasts. A 2025 study reported telomere effects in cultured normal cells and breast-cancer cell lines, including activation of an alternative telomere-lengthening pathway in cancer cells.

These cell-culture observations do not demonstrate that Epitalon reverses aging, lengthens human life, improves healthspan, or is safe over the long term. Telomere biology is complex; longer telomeres are not automatically beneficial in every context. The cancer-cell finding is a reason for careful investigation, not proof that Epitalon causes cancer.

The human-evidence scoreboard

Selank has preliminary human anxiety signals but limited replication and long-term safety data.

Semax has small human studies demonstrating biological activity and exploratory neurological signals, but no convincing foundation for broad nootropic or neurodegenerative-disease claims.

Epitalon has intriguing cell-level biology but lacks persuasive compound-specific human evidence for longevity, age reversal, or clinically meaningful sleep improvement.

Mechanistic plausibility matters. A biomarker can matter. The decisive question is whether a compound produces a replicated, patient-centered benefit with an acceptable safety profile and a reliable product. None of these three has cleared that bar for the broad claims commonly made online.

United States regulatory and safety context

As of August 28, 2026, none of the three is approved by the United States Food and Drug Administration, and none is a component of an FDA-approved drug.

The agency lists compounded Selank acetate, Semax, and Epitalon among substances that may present significant safety risks or for which critical safety information is lacking. Peptide products raise concerns beyond the intended molecule, including identity, potency, sterility, aggregation, peptide-related impurities, and immunogenicity.

In its July 2026 review, the agency reported insufficient information to characterize intranasal Semax safety, no proposed-route subcutaneous safety data, no published human pharmacokinetic studies, and no published clinical immunogenicity studies. For Epitalon, the agency reported that it had not identified safety information for the proposed route. It also identified important human-safety gaps for Selank acetate.

The agency proposed that Semax and Epitalon free-base and acetate forms not be included on the section 503A bulks list. That regulatory process should not be misrepresented as drug approval, nor reduced to the unsupported shorthand “banned.” Availability can depend on the exact substance, timing, applicable law, pharmacy practice, and patient-specific circumstances.

For patients who join Dr. Carlton’s practice, the safer clinical pathway is not an anonymous overseas research-market purchase. It begins with an individual medical evaluation and, when clinically and legally appropriate, a patient-specific prescription filled through a licensed 503A compounding pharmacy with traceable sourcing and documentation. That pathway does not convert an unapproved drug into an FDA-approved product, but it materially changes the quality, accountability, and clinical-oversight conversation.

Bottom line

Selank is principally an anxiety hypothesis. Semax is principally a neuroprotection and cognition hypothesis. Epitalon is principally a circadian-resetting and longevity hypothesis—with the body-clock question offering the most clinically intuitive reason for the current curiosity.

Their shared story is compelling biology paired with limited, uneven human evidence and substantial product-quality and safety uncertainty. Anyone considering an emerging therapy should discuss the exact compound, route, source, and personal risk factors with a qualified clinician rather than relying on a product label or promotional claim.

This article is educational and does not provide individualized medical advice, diagnosis, dosing, or a recommendation to use an unapproved product.

Work with Dr. Kish Carlton

Learn about working with Dr. Kish Carlton at www.MindBodySpirit-DPC.com. There is no pressure — it is simply a place to read more and decide whether this practice fits your goals.

References

Medical disclaimer

This article is educational and does not provide individualized medical advice, diagnosis, dosing, or a recommendation to use an unapproved product.